该公司报告的Q2收入高于预期,导致股票价格上涨和评级提高。 Collegium Pharmaceutical reported better-than-expected Q2 earnings, leading to stock price increase and upgraded ratings.

科利吉亚制药公司的第二季度收益比预期好,每股收益为1.62美元,收入为145.28万美元,同比增长7.2%. Collegium Pharmaceutical reported better-than-expected Q2 earnings, with EPS of $1.62 and revenue of $145.28M, up 7.2% YoY. 其股票价格在新闻上升至35.50美元。 Its stock price increased to $35.50 on the news. Piper Sandler分析师对COLL维持“中性”评级，目标价下调至37美元，而杰富瑞金融集团（Jefferies Financial Group）将评级上调至“买入”，HC Wainwright也将评级上调至“买入”，目标价为47美元。 Analysts at Piper Sandler maintained a "neutral" rating on COLL, with a lowered price target of $37, while Jefferies Financial Group upgraded their rating to "buy" and HC Wainwright also upgraded to "buy" with a $47 price target. 该公司的市值为116亿美元,共识评级为"中等购买",平均目标价格为42美元. The company's market cap is $1.16B and has a consensus rating of "Moderate Buy" with an average target price of $42.